An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- The Impact of Recent Screening Recommendations on Prostate Cancer Screening in a Large Health Care SystemJournal of Urology, 2014
- Clinical Utility of an Epigenetic Assay to Detect Occult Prostate Cancer in Histopathologically Negative Biopsies: Results of the MATLOC StudyJournal of Urology, 2013
- The impact of PLCO control arm contamination on perceived PSA screening efficacyCancer Causes & Control, 2012
- Prostate specific antigen screening for prostate cancer: Knowledge of, attitudes towards, and utilization among primary care physiciansUrologic Oncology: Seminars and Original Investigations, 2012
- Baseline Prostate-Specific Antigen Testing at a Young AgeEuropean Urology, 2012
- PSA screening: determinants of primary-care physician practice patternsProstate Cancer and Prostatic Diseases, 2011
- Prostate‐specific antigen 1.5–4.0 ng/mL: a diagnostic challenge and danger zoneBJU International, 2011
- Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate‐specific antigen at or before age 50Cancer, 2010
- Mortality Results from a Randomized Prostate-Cancer Screening TrialNew England Journal of Medicine, 2009
- Prostate Specific Antigen Changes as Related to the Initial Prostate Specific Antigen: Data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening TrialJournal of Urology, 2006